- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05510167
Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognition in AF (PLATINUM)
August 18, 2022 updated by: Andrea Natale, Texas Cardiac Arrhythmia Research Foundation
Impact of Post-ablation Alcohol Intake on Arrhythmia Recurrence, Quality of Life and Cognition in Patients With Atrial Fibrillation
Earlier studies have shown a dose-dependent relationship between alcohol intake and incident atrial fibrillation (AF) as well as a causal link with several risk factors for AF such as hypertension, obesity and sleep apnea.
However, the effect of drinking (alcohol) on post-ablation outcome such as arrhythmia recurrence, quality of life (QoL) and cognitive function in AF patients is unclear.
Therefore, we aim to find the answer for a very frequently asked question, "is it safe to continue drinking alcohol (at the pre-ablation level) following catheter ablation OR should the intake be reduced for better outcome?", in this randomized trial.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
- BACKGROUND Earlier studies have not only reported alcohol-abstinence to be associated with lower recurrence of AF in patients receiving non-ablative antiarrhythmic therapy, but also unfavorable outcome among regular drinkers (high frequency and quantity) compared to non-drinkers undergoing AF ablation (1-3). In a meta-analysis of 14 studies, where the effect measures for AF associated with highest vs lowest alcohol intake were pooled for analysis, not consuming alcohol was observed to be the most favorable in terms of AF risk reduction (4). Larsson et al reported alcohol drinking, even in moderate quantity, to be a risk factor for incident AF, whereas Zhang et al observed moderate drinking to be associated with high AF risk in men only and not in females (5, 6). Moreover, a causal link between alcohol intake and other cardiovascular morbidities such as obesity, hypertension, left ventricular dysfunction and sleep apnea that are known risk factors for AF has been documented by several studies (1). Thus, we know that alcohol consumption, even in moderate quantity, increases the risk for AF, although may not be across genders. Observational studies also have shown unfavorable procedure outcome to be more common in drinkers compared to non-drinkers receiving AF ablation. However, there is no randomized data to support the latter statement. Additionally, there are no data on the influence of alcohol intake on the cognitive function and QoL in AF patients receiving catheter ablation. Therefore, this investigator-initiated, randomized trial has been designed to examine the impact of alcohol intake vs abstinence on arrhythmia recurrence and burden, QoL and cognitive function in regular drinkers undergoing their first catheter ablation.
- STUDY RATIONALE We hypothesize that alcohol-abstinence will significantly improve the procedural outcome, QoL and cognitive function in the study population compared to the non-abstinence cohort.
- STUDY OBJECTIVES Primary Objective Arrhythmia recurrence across all AF types at 8 months after the ablation procedure, off- or on-antiarrhythmic drug (AAD) Secondary Objective 1) Change in QoL score measured by AFEQT survey at baseline and 6 months 2) Change in cognitive function measured by MoCA survey 3) Arrhythmia burden at follow-up
Study period will start from the day after the procedure and continue for 8 months (2-month blanking period+ 6 months follow-up).
Group 1: Complete abstinence or ≤2 drinks/week in group 1 during the study period Group 2: Allowed to continue their pre-ablation drinking habit
Study Type
Interventional
Enrollment (Anticipated)
130
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andrea Natale
- Phone Number: 5125448186
- Email: dr.natale@gmail.com
Study Contact Backup
- Name: Sanghamitra Mohanty
- Phone Number: 5127842651
- Email: mitra1989@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- AF patients that regularly consume >5 alcoholic drink (*12 g of pure alcohol/drink)/week
- Paroxysmal or persistent AF
- First catheter ablation History of alcohol-induced arrhythmia
- Willing to sign the written informed consent
Exclusion Criteria:
- Binge drinkers (alcohol dependence)
- Non-drinkers
- LVEF <35%
- Psychiatric conditions
- MoCA score ≤ 17 on Montreal Cognitive Assessment (MoCA)
- Patients with established dementia
- Medically unstable patients (acute/unstable or poorly controlled problems that would demand focused, relatively urgent or emergent medical attention)
- Unwilling for alcohol-abstinence
- Long-standing persistence AF
- Patient under legal protection
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Study
Complete abstinence or ≤2 drinks/week in group 1 during the study period
|
Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
|
|
ACTIVE_COMPARATOR: Control
Allowed to continue their pre-ablation drinking habit
|
Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arrhythmia recurrence
Time Frame: 8 months after the ablation procedure for AF
|
Arrhythmia recurrence across all AF types at 8 months after the ablation procedure, off- or on-antiarrhythmic drug (AAD)
|
8 months after the ablation procedure for AF
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in QoL
Time Frame: 6 months after the blanking period of 2 months
|
Change in QoL measured by AFEQT survey at baseline and 6 months
|
6 months after the blanking period of 2 months
|
|
Change in cognitive function
Time Frame: 6 months after the blanking period of 2 months
|
Change in cognitive function measured by MoCA survey
|
6 months after the blanking period of 2 months
|
|
Arrhythmia burden
Time Frame: 6-8 months following ablation
|
Arrhythmia burden at follow-up
|
6-8 months following ablation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Andrea Natale, Texas Cardiac Arrhythmia Institute, St.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
August 22, 2022
Primary Completion (ANTICIPATED)
August 1, 2024
Study Completion (ANTICIPATED)
August 1, 2025
Study Registration Dates
First Submitted
August 15, 2022
First Submitted That Met QC Criteria
August 18, 2022
First Posted (ACTUAL)
August 22, 2022
Study Record Updates
Last Update Posted (ACTUAL)
August 22, 2022
Last Update Submitted That Met QC Criteria
August 18, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCAI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Medtronic Cardiac Ablation SolutionsRecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)Australia, United States, France, Belgium, Switzerland, Czechia
-
Boston Scientific CorporationRecruitingAtrial Fibrillation (AF) | Persistant Atrial FibrillationUnited States, Spain, Belgium, France, Netherlands, Germany, Hong Kong
-
China National Center for Cardiovascular DiseasesRecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field AblationChina
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Yunlong WangBoston Scientific Corporation; Beijing Huahsia FoundationNot yet recruitingAtrial Fibrillation (AF) | Atrial Fibrillation Catheter AblationChina
-
Medtronic Cardiac Ablation SolutionsNot yet recruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation
-
University Medical Centre LjubljanaEnrolling by invitationPersistent Atrial Fibrillation | Persistent Atrial Fibrillation LongstandingSlovenia
-
CortexAblacon, Inc.Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Boston Scientific CorporationRecruitingParoxysmal Atrial Fibrillation | Persistent Atrial FibrillationHong Kong, Czechia, Croatia, Taiwan
Clinical Trials on Study arm
-
University of New MexicoAmerican Diabetes AssociationCompleted
-
University of ZurichCompletedLung Transplant Rejection | Lung Transplant Failure and RejectionSwitzerland
-
Tze-Fan ChaoRecruitingAtrial Fibrillation (AF)Taiwan
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingInflammatory Bowel Diseases | Psoriasis
-
Boston Scientific CorporationTerminated
-
University of FloridaTerminatedPain, PostoperativeUnited States
-
Philip LoizouUnknown
-
University of British ColumbiaCanadian Cancer Society (CCS)Completed
-
University of British ColumbiaCanadian Cancer Society (CCS)CompletedCancer Prevention
-
Gangnam Severance HospitalCompleted